Associate Sponsors

Co-sponsor

Home / India News / Cadila's Dabhasa facility receives Establishment Inspection Report

Cadila's Dabhasa facility receives Establishment Inspection Report

Image
Capital Market
Last Updated : Dec 06 2019 | 3:50 PM IST
LinkedIN IconFacebook Icon
Cadila Healthcare announced that the company's API manufacturing facility located at Dabhasa, Gujarat has received an Establishment Inspection Report (EIR). The USFDA had conducted an inspection at the facility from 7 to 11 October 2019. The EIR report stated that the classification of the facility is 'No Action Indicated (NAI)'.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

Connect with us on WhatsApp

More From This Section

Shakti Pumps (India) receives revised credit ratings from CARE

Bank of Maharashtra keeps MCLR and RLLR unchanged

Canara Bank announces MCLR and Repo Rate linked Lending Rate

Dr Reddys Laboratories launches Deferasirox Tablets for Oral Suspension

First Published: Dec 06 2019 | 3:28 PM IST

Explore News

Next Story